Market closed

Fulgent Genetics/$FLGT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Ticker

$FLGT
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Providers & Services
Headquarters
El Monte, United States

Employees

1,184
Website
www.fulgentgenetics.com

Fulgent Genetics Metrics

BasicAdvanced
$549M
-
-$5.50
1.51
-

$549M

1.51

$27.56

$16.56

256K

4.413

3.757

0.67

0.876

-4.15%

-14.35%

1.939

0.48

0.56

-18.782

-3.02%

157.03%

-35.52%

-33.93%

What the Analysts think about Fulgent Genetics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.

Fulgent Genetics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Fulgent Genetics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Fulgent Genetics News

AllArticlesVideos
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

Seeking Alpha·3 weeks ago
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FLGT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fulgent Genetics stock?

Fulgent Genetics (FLGT) has a market cap of $549M as of January 15, 2025.

What is the P/E ratio for Fulgent Genetics stock?

The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of January 15, 2025.

Does Fulgent Genetics stock pay dividends?

No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Fulgent Genetics dividend payment date?

Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.

What is the beta indicator for Fulgent Genetics?

Fulgent Genetics (FLGT) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.